These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29571973)

  • 1. Options for design of real-world impact studies of single-dose vaccine schedules.
    Franceschi S; Clifford GM; Baussano I
    Vaccine; 2018 Aug; 36(32 Pt A):4816-4822. PubMed ID: 29571973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact.
    Gilca V; Salmerón-Castro J; Sauvageau C; Ogilvie G; Landry M; Naus M; Lazcano-Ponce E
    Vaccine; 2018 Aug; 36(32 Pt A):4800-4805. PubMed ID: 29887322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs.
    Markowitz LE; Drolet M; Perez N; Jit M; Brisson M
    Vaccine; 2018 Aug; 36(32 Pt A):4806-4815. PubMed ID: 29802000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
    Burger EA; Campos NG; Sy S; Regan C; Kim JJ
    Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.
    D'Addario M; Redmond S; Scott P; Egli-Gany D; Riveros-Balta AX; Henao Restrepo AM; Low N
    Vaccine; 2017 May; 35(22):2892-2901. PubMed ID: 28455170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.
    Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S
    Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
    Murillo R; Ordóñez-Reyes C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
    Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
    BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
    Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
    Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
    BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
    Regan DG; Philp DJ; Hocking JS; Law MG
    Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
    Tan N; Sharma M; Winer R; Galloway D; Rees H; Barnabas RV
    Vaccine; 2018 Aug; 36(32 Pt A):4830-4836. PubMed ID: 29891348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.
    Man I; Georges D; de Carvalho TM; Ray Saraswati L; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Berkhof J; Sankaranarayanan R; Bogaards JA; Basu P; Baussano I
    Lancet Oncol; 2022 Nov; 23(11):1419-1429. PubMed ID: 36174583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
    Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
    Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.
    Sankaranarayanan R; Joshi S; Muwonge R; Esmy PO; Basu P; Prabhu P; Bhatla N; Nene BM; Shaw J; Poli URR; Verma Y; Zomawia E; Pimple S; Tommasino M; Pawlita M; Gheit T; Waterboer T; Sehr P; Pillai MR;
    Vaccine; 2018 Aug; 36(32 Pt A):4783-4791. PubMed ID: 29551226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis.
    Bénard É; Drolet M; Laprise JF; Gingras G; Jit M; Boily MC; Bloem P; Brisson M
    Lancet Public Health; 2023 Oct; 8(10):e788-e799. PubMed ID: 37777288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.